EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Anti‐CD40L therapy prevents the formation of precursor lesions to gastric B‐cell MALT lymphoma in a mouse model

Le Ying iD, Phoebe Liu, Zhoujie Ding iD, Georgie Wray-McCann, Jack Emery, Nina Colon, Lena Hm Le, Le Son Tran iD, Ping Xu, Liang Yu, Dana J Philpott iD, Yugang Tu und 5 weitere

The Journal of Pathology · 2023

DOI: 10.1002/path.6053 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pathology, 2023. Verfasst von Le Ying und 16 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, VIC, Australia. Hauptthemen laut MEDLINE: Stomach Neoplasms, Helicobacter Infections, Helicobacter pylori, Lymphoma, B-Cell, Marginal Zone. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Health and Medical Research Council, National Medical Research Council, Tanoto Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mucosa‐associated lymphoid tissue (MALT) lymphoma is a B‐cell tumour that develops over many decades in the stomachs of individuals with chronic Helicobacter pylori infection. We developed a new mouse model of human gastric MALT lymphoma in which mice with a myeloid‐specific deletion of the innate immune molecule, Nlrc5, develop precursor B‐cell lesions to MALT lymphoma at only 3 months post‐ Helicobacter infection versus 9–24 months in existing models. The gastric B‐cell lesions in the Nlrc5 knockout mice had the histopathological features of the human disease, notably lymphoepithelial‐like lesions, centrocyte‐like cells, and were infiltrated by dendritic cells (DCs), macrophages, and T‐cells (CD4 + , CD8 + and Foxp3 + ). Mouse and human gastric tissues contained immune cells expressing immune checkpoint receptor programmed death 1 (PD‐1) and its ligand PD‐L1, indicating an immunosuppressive tissue microenvironment. We next determined whether CD40L, overexpressed in a range of B‐cell malignancies, may be a potential drug target for the treatment of gastric MALT lymphoma. Importantly, we showed that the administration of anti‐CD40L antibody either coincident with or after establishment of Helicobacter infection prevented gastric B‐cell lesions in mice, when compared with the control antibody treatment. Mice administered the CD40L antibody also had significantly reduced numbers of gastric DCs, CD8 + and Foxp3 + T‐cells, as well as decreased gastric expression of B‐cell lymphoma genes. These findings validate the potential of CD40L as a therapeutic target in the treatment of human gastric B‐cell MALT lymphoma. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsHelicobacter InfectionsHelicobacter pyloriLymphoma, B-Cell, Marginal ZoneB-LymphocytesTumor MicroenvironmentLymphoma, Non-HodgkinForkhead Transcription FactorsIntracellular Signaling Peptides and ProteinsMiceAnimalsCD40 Ligand

Stichwörter der Autor:innen

APRILB-cellBAFFCD40 ligandHelicobacterMALT lymphomaNLRC5PD-L1multiplex immunohistochemistry

Substanzen

CD40 LigandForkhead Transcription FactorsIntracellular Signaling Peptides and ProteinsNLRC5 protein, humanNLRC5 protein, mouse

Autor:innen und Institutionen

  • Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, VIC, Australia.
  • Department of Molecular and Translational Science, Monash University, Clayton, VIC, Australia.
  • Department of Immunology, University of Toronto, Toronto, ON, Canada.
  • Department of Immunology and Pathology, Central Clinical School, Monash University, Clayton, VIC, Australia.
  • Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Solna, Sweden.
  • Department of Tea Science, Zhejiang University, Hangzhou, PR China.

ORCID-Profile: Le Ying, Zhoujie Ding, Le Son Tran, Dana J Philpott, Choon K Ong, Richard L Ferrero

Förderung

  • National Health and Medical Research Council
  • National Medical Research Council
  • Tanoto Foundation
  • U.S. Department of Defense
  • Public Health Agency of Canada

Zitieren

APA

Ying, L., Liu, P., Ding, Z., Wray-McCann, G., Emery, J., Colon, N., Le, L. H., Tran, L. S., Xu, P., Yu, L., Philpott, D. J., Tu, Y., Cheah, D. M., Cheng, C. L., Lim, S. T., Ong, C. K., & Ferrero, R. L. (2023). Anti‐CD40L therapy prevents the formation of precursor lesions to gastric B‐cell MALT lymphoma in a mouse model. The Journal of Pathology. https://doi.org/10.1002/path.6053

Vancouver

Ying L, Liu P, Ding Z, Wray-McCann G, Emery J, Colon N, et al. Anti‐CD40L therapy prevents the formation of precursor lesions to gastric B‐cell MALT lymphoma in a mouse model. The Journal of Pathology. 2023. doi:10.1002/path.6053

BibTeX
@article{Ying2023,
  author = {Ying, Le and Liu, Phoebe and Ding, Zhoujie and Wray-McCann, Georgie and Emery, Jack and Colon, Nina and Le, Lena Hm and Tran, Le Son and Xu, Ping and Yu, Liang and Philpott, Dana J and Tu, Yugang and Cheah, Daryl Mz and Cheng, Chee L and Lim, Soon T and Ong, Choon K and Ferrero, Richard L},
  title = {Anti‐CD40L therapy prevents the formation of precursor lesions to gastric B‐cell MALT lymphoma in a mouse model},
  journal = {The Journal of Pathology},
  year = {2023},
  doi = {10.1002/path.6053}
}
Kostenlos starten →